Literature DB >> 22645849

Impact of aortic stenosis severity and its interaction with prosthesis-patient mismatch on operative mortality following aortic valve replacement.

Nicolas Girerd1, Patrick Mathieu, Jean G Dumesnil, Julien Magne, Eric Charbonneau, François Dagenais, Eric Dumont, Pierre Voisine, Richard Baillot, Philippe Pibarot.   

Abstract

BACKGROUND AND AIM OF THE STUDY: The optimal timing of aortic valve replacement (AVR) in patients with severe aortic stenosis (AS) is a source of debate. Moreover, it has been shown previously that prosthesis-patient mismatch (PPM) is an independent predictor of operative mortality after AVR. The study aim was to assess the effect of the preoperative severity of AS and its interaction with PPM with respect to operative mortality after AVR.
METHODS: The data were analyzed from 2,104 consecutive patients who had undergone AVR for severe AS. The patients were allocated to tertiles according to their preoperative indexed aortic valve area (AVAi) as: < 0.35 cm2/m2, 0.35 to 0.43 cm2/m2, and > 0.43 cm2/m2. PPM was defined as a projected postoperative indexed effective orifice area (EOAi) of the implanted prosthesis < 0.85 cm2/m2.
RESULTS: The operative mortality was 5.7% (n = 120). On multivariate analysis, an independent association was identified between the preoperative severity of AS and operative mortality (odds ratio [OR] = 2.00, p = 0.03 for AVAi < 0.35 cm2/m2; OR = 1.39, p = 0.32 for AVAi 0.35-0.43 cm2/m2). Notably, the impact of PPM was more important in patients with more severe AS (p = 0.046 for AVAi x EOAi interaction).
CONCLUSION: The study results confirmed that very severe AS (AVAi < 0.35 cm2/m2) is independently associated with operative mortality after AVR. The results also emphasized the importance of avoiding PPM in these patients.

Entities:  

Mesh:

Year:  2012        PMID: 22645849

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  1 in total

Review 1.  Prosthesis-Patient Mismatch After Aortic Valve Replacement.

Authors:  Abdellaziz Dahou; Haïfa Mahjoub; Philippe Pibarot
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.